These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24262439)

  • 21. Monoclonal antibody therapy for breast cancer: herceptin.
    Finn RS; Slamon DJ
    Cancer Chemother Biol Response Modif; 2003; 21():223-33. PubMed ID: 15338747
    [No Abstract]   [Full Text] [Related]  

  • 22. [In situ hybridization in clinical pathology. Significance of polysomy 17 for HER2 determination and genetic tumor heterogeneity in breast cancer].
    Gaiser T; Rüschoff J; Moll R
    Pathologe; 2012 Nov; 33 Suppl 2():307-10. PubMed ID: 23052344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet?
    Yaziji H; Gown AM
    Hum Pathol; 2004 Feb; 35(2):143-6. PubMed ID: 14991529
    [No Abstract]   [Full Text] [Related]  

  • 24. Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration.
    Triulzi T; De Cecco L; Sandri M; Prat A; Giussani M; Paolini B; Carcangiu ML; Canevari S; Bottini A; Balsari A; Menard S; Generali D; Campiglio M; Di Cosimo S; Tagliabue E
    Oncotarget; 2015 Sep; 6(29):28173-82. PubMed ID: 26334217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health care costs: how do we decide value? When do we decide? How do we particularize the decisions?
    Theriault RL
    Oncologist; 2012; 17(2):157-9. PubMed ID: 22302226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Novel target therapies used in breast cancer management].
    Semiglazova TIu; Semiglazov VV; Filatova LV; Gershanovich ML; Chudenko VA; Latipova DKh; Luk'ianchikova VS; Dashian GA; Paltuev RM
    Vopr Onkol; 2011; 57(5):592-600. PubMed ID: 22238928
    [No Abstract]   [Full Text] [Related]  

  • 27. Additive effects of trastuzumab and genistein on human breast cancer cells.
    Lattrich C; Lubig J; Springwald A; Goerse R; Ortmann O; Treeck O
    Anticancer Drugs; 2011 Mar; 22(3):253-61. PubMed ID: 21160418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. "Build quality in"--HER2 testing in the real world.
    Zujewski JA
    J Natl Cancer Inst; 2002 Jun; 94(11):788-9. PubMed ID: 12048261
    [No Abstract]   [Full Text] [Related]  

  • 29. Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer.
    Tanioka M; Sakai K; Sudo T; Sakuma T; Kajimoto K; Hirokaga K; Takao S; Negoro S; Minami H; Nakagawa K; Nishio K
    Breast Cancer Res Treat; 2014 Oct; 147(3):513-25. PubMed ID: 25200445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer.
    Berghoff AS; Bago-Horvath Z; Dubsky P; Rudas M; Pluschnig U; Wiltschke C; Gnant M; Steger GG; Zielinski CC; Bartsch R
    Breast J; 2013; 19(2):149-55. PubMed ID: 23350584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spotlight on trastuzumab as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
    Garnock-Jones KP; Keating GM; Scott LJ
    BioDrugs; 2010 Jun; 24(3):207-9. PubMed ID: 20462285
    [No Abstract]   [Full Text] [Related]  

  • 32. What is the ideal HER2 test for Herceptin therapy?
    Jpn J Clin Oncol; 2000 Apr; 30(4):208-9, 211. PubMed ID: 10830993
    [No Abstract]   [Full Text] [Related]  

  • 33. Counterpoint: Both immunohistochemistry and fluorescence in situ hybridization play important roles for HER2 evaluation.
    Bloom KJ; Cote RJ
    Clin Chem; 2011 Jul; 57(7):983-5. PubMed ID: 21558454
    [No Abstract]   [Full Text] [Related]  

  • 34. The role of overexpressed HER2 in transformation.
    Neve RM; Lane HA; Hynes NE
    Ann Oncol; 2001; 12 Suppl 1():S9-13. PubMed ID: 11521729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What is the mechanism of progression with trastuzumab treatment--escape or resistance?
    Sendur MA; Aksoy S; Özdemir NY; Zengin N; Altundağ K
    Asian Pac J Cancer Prev; 2012; 13(11):5915-6. PubMed ID: 23317282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormone receptor status affects locoregional control in HER2-positive breast cancer treated with trastuzumab.
    Barton MK
    CA Cancer J Clin; 2012; 62(5):281-2. PubMed ID: 22847535
    [No Abstract]   [Full Text] [Related]  

  • 37. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.
    Valabrega G; Montemurro F; Aglietta M
    Ann Oncol; 2007 Jun; 18(6):977-84. PubMed ID: 17229773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Isolated effect of the monoclonal antibody trastuzumab (Herceptin) in a patient with local recurrence of breast carcinoma with HER-2 hyperexpression. ].
    Del Giglio A
    Rev Assoc Med Bras (1992); 2006; 52(4):202. PubMed ID: 16967134
    [No Abstract]   [Full Text] [Related]  

  • 39. The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.
    Slamon DJ
    Oncologist; 2004; 9 Suppl 3():1-3. PubMed ID: 15163840
    [No Abstract]   [Full Text] [Related]  

  • 40. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.